FDA Defines Good Review Management; No Data In Labeling Negotiations
Executive Summary
Last-minute labeling negotiations are not an appropriate time for presentation of additional data by NDA sponsors, FDA said in a draft guidance on review practices
You may also be interested in...
Good Review Management Guidance To Be Tested By “Root Causes” Analysis
FDA will evaluate the impact of its Good Review Management Principles project through a prospective analysis of NME submissions, beginning with fiscal year 2005
Good Review Management Guidance To Be Tested By “Root Causes” Analysis
FDA will evaluate the impact of its Good Review Management Principles project through a prospective analysis of NME submissions, beginning with fiscal year 2005
FDA Finalizing Review Principles Guidance; Complete Submissions Urged
FDA's guidance on good review management principles is entering the final clearance stage, Office of New Drugs Director John Jenkins, MD, said during the Drug Information Association annual meeting in Washington, D.C. June 16